A pilot study to evaluate the vascular endothelial growth factor receptor tyrosine kinase inhibitor AZD2171 and chemotherapy in locally advanced and inflammatory breast cancer.
Denduluri
Neelima
N
Breast Cancer Section, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Tan
Antoinette R
AR
Walshe
Janice
J
Berman
Arlene
A
Yang
Sherry X
SX
Chow
Catherine K
CK
Swain
Sandra M
SM
D001943:Breast Neoplasms / Q000188:drug therapy* / Q000209:etiology; D017322:Clinical Trials, Phase II as Topic; D004791:Enzyme Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007249:Inflammation / Q000188:drug therapy; D010865:Pilot Projects; D011799:Quinazolines / Q000009:adverse effects / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D040262:Receptors, Vascular Endothelial Growth Factor / Q000037:antagonists & inhibitors*; D007211:Indoles
D004791:Enzyme Inhibitors; D011799:Quinazolines; D040262:Receptors, Vascular Endothelial Growth Factor; C500926:cediranib; D007211:Indoles